可公开获取的出版物、注册库与III期试验方案之间的比较表明选择性结局报告持续存在
该研究比较了2012年1月1日至2015年6月30日发表于《新英格兰医学杂志》《柳叶刀》《美国医学会杂志》和《英国医学杂志》且有方案可查的299项III期随机对照试验,发现25项试验(8.4%)的出版物与方案在主要结局上存在差异,其中60.0%的差异倾向于统计学显著结果;注册库在79.3%的试验中可作为方案的有效替代。
要点
- 299项III期随机对照试验中,25项(8.4%)出版物与方案的主要结局存在差异。
- 差异类型包括方案主要结局被降为非主要结局(11项,3.7%)、被省略(10项,3.3%)等。
- 存在差异的试验中,15项(60.0%)的差异倾向于统计学显著结果。
核心结论
- 尽管方案可公开获取,选择性结局报告仍在一小部分III期随机对照试验中持续存在。
研究设计与样本
- 研究识别了2012年1月1日至2015年6月30日发表于《新英格兰医学杂志》《柳叶刀》《美国医学会杂志》和《英国医学杂志》且有方案可查的299项III期随机对照试验,评估方案与注册库(文章)之间主要结局的一致性。
主要发现
- 299项III期随机对照试验中,25项(8.4%)的出版物与方案在主要结局上存在差异。
- 差异类型包括:方案定义的主要结局在出版物中被报告为非主要结局(11项,3.7%)、方案定义的主要结局在出版物中被省略(10项,3.3%)、出版物中引入新主要结局(8项,2.7%)、方案定义的非主要结局在出版物中被报告为主要结局(4项,1.3%)、主要结局评估时间不同(4项,1.3%)。
- 存在主要结局差异的试验中,15项(60.0%)的差异倾向于统计学显著结果。
- 在299项试验中,237项(79.3%)的注册库在主要结局方面可视为方案的有效替代。
局限性
- 仅纳入来自四份领先期刊的研究,可能导致选择偏倚并限制该发现的普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The decision to make protocols of phase III randomized controlled trials (RCTs) publicly accessible by leading journals was a landmark event in clinical trial reporting. Here, we compared primary outcomes defined in protocols with those in publications describing the trials and in trial registration. STUDY DESIGN AND SETTING: We identified phase III RCTs published between January 1, 2012, and June 30, 2015, in The New England Journal of Medicine, The Lancet, The Journal of the American Medical Association, and The BMJ with available protocols. Consistency in primary outcomes between protocols and registries (articles) was evaluated. RESULTS: We identified 299 phase III RCTs with available protocols in this analysis. Out of them, 25 trials (8.4%) had some discrepancy for primary outcomes between publications and protocols. Types of discrepancies included protocol-defined primary outcome reported as nonprimary outcome in publication (11 trials, 3.7%), protocol-defined primary outcome omitted in publication (10 trials, 3.3%), new primary outcome introduced in publication (8 trials, 2.7%), protocol-defined nonprimary outcome reported as primary outcome in publication (4 trials, 1.3%), and different timing of assessment of primary outcome (4 trials, 1.3%). Out of trials with discrepancies in primary outcome, 15 trials (60.0%) had discrepancies that favored statistically significant results. Registration could be seen as a valid surrogate of protocol in 237 of 299 trials (79.3%) with regard to primary outcome. CONCLUSION: Despite unrestricted public access to protocols, selective outcome reporting persists in a small fraction of phase III RCTs. Only studies from four leading journals were included, which may cause selection bias and limit the generalizability of this finding.
引用
- Zhang S, Liang F, Li W, et al. Comparison between publicly accessible publications, registries, and protocols of phase III trials indicated persistence of selective outcome reporting. J Clin Epidemiol. 2017. PMID: 28757260. doi:10.1016/j.jclinepi.2017.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。